Epigral Ltd (EPIGRAL) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company reported a marginal sales volume growth of 2% in Q2 FY26, but revenue declined by 4% due to reduced price realizations in certain product categories.
- Performance was impacted by an extended monsoon season, subdued market demand, and planned maintenance activities, leading to a decline in both value and volume for H1 FY26.
- Despite lower realizations and plant utilization, the EBITDA margin was maintained at a healthy 25%, with expectations for improvement as plant utilization increases in H2 FY26.
- Major CapEx projects, including the doubling of CPVC and Epichlorohydrin capacity and a new wind-solar hybrid power plant, are progressing on schedule and within budget, aiming to increase the revenue contribution from derivatives and specialty business to 70%.
- The company is actively working on two new sizable projects to drive growth beyond FY 2028, focusing on import substitution products with high, double-digit growth potential and strong ROCE.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.